Actionable news
All posts from Actionable news
Actionable news in OMER: Omeros Corporation,

Omeros Corporation Announces Exclusive Middle East Distribution Agreement for OMIDRIA®


Omeros Corporation (OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced entry into an exclusive supply and distribution agreement for the sale of OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% in the Kingdom of Saudi Arabia, the United Arab Emirates and other countries in the Middle East with ITROM Trading Drug Store (ITROM). ITROM is Dubai-based and an internationally recognized pharmaceutical marketing and distribution company specializing in ophthalmology. Under the agreement, ITROM will be responsible for obtaining marketing authorizations for OMIDRIA within the licensed territory and for marketing, selling and distributing product supplied by Omeros. Existing ophthalmology medical sales representatives employed by ITROM are expected to be reinforced with additional medical sales representatives that will be dedicated to OMIDRIA.

“We expect that ITROM will begin sales of OMIDRIA later this year,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. “This marks the start of our expansion to international markets, and we look forward to bringing the benefits of OMIDRIA to patients outside of the U.S.”

“ITROM and our affiliate companies have been successfully representing innovative and breakthrough products within our region for several years now,” stated ITROM Pharmaceutical Group’s Managing Director Dr. Ismail Soboh. “We believe that Omidria definitely falls in this highly-sought-after category of products.”


Omeros’ OMIDRIA® (phenylephrine and ketorolac injection) 1% / 0.3% is the only FDA-approved product for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. OMIDRIA also is the only NSAID-containing product FDA-approved for intraocular use. In post-launch studies across conventional and femtosecond laser-assisted cataract surgery, OMIDRIA has been shown (1) to be effective in patients with intraoperative floppy iris syndrome (IFIS), pseudoexfoliation and other ophthalmic conditions, (2) to significantly reduce complication rates, use of pupil-expanding devices and...